Xcelience Appoints Clinical Supplies VP of New UK Site
Xcelience appoints Clinical Supplies VP of its new Birmingham, United Kingdom site.
Xcelience has hired Joseph Iacobucci as vice president of Clinical Supplies and Services to oversee Xcelience’s first international expansion in Birmingham, UK. Iacobucci has nearly 30 years of experience in clinical packaging and supply services, including 23 years as a VP for Clinical Systems, Inc. His responsibilities there included business development of contract services and software products. He also served as an internal resource for software product development for clinical label generation systems and clinical inventory management systems. He is a registered pharmacist, a member of Global Clinical Supplies Group, Equal Partners in Clinical Supplies, and the International Society of Pharmaceutical Engineers.
The new depot labeling facility, set to begin operations in February 2014, will provide a central distribution hub for labeling and distribution throughout Europe. Iacobucci is the second addition to the executive management team this fall, after the hiring of Lindon Fellows as COO in September.
Source: Xcelience
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
